Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-07-19
2011-07-19
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S238000, C544S333000, C544S353000, C544S405000, C546S113000, C546S121000, C546S167000, C546S208000, C546S280400, C548S127000, C548S159000, C548S217000, C548S310100, C548S335100, C548S374100, C548S469000, C549S058000, C549S059000, C549S471000
Reexamination Certificate
active
07981925
ABSTRACT:
Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity.
REFERENCES:
patent: 4658040 (1987-04-01), Baird et al.
patent: 6323227 (2001-11-01), Klein et al.
patent: 6919359 (2005-07-01), Piotrowski et al.
patent: 2004/0142980 (2004-07-01), Finzel et al.
patent: 2006/0199845 (2006-09-01), Sun et al.
patent: 2007/0249050 (2007-10-01), Chen et al.
patent: 2007/0249051 (2007-10-01), Bohnert et al.
patent: 2007/0249609 (2007-10-01), Chen et al.
patent: 2007/0249661 (2007-10-01), Chen et al.
patent: 2007/0254363 (2007-11-01), Chen et al.
patent: 2007/0254912 (2007-11-01), Chen et al.
patent: 2007/0254925 (2007-11-01), Vo et al.
patent: 2007/0254926 (2007-11-01), Jiang et al.
patent: 2009/0137659 (2009-05-01), Velicelebi et al.
patent: WO 94/12505 (1994-06-01), None
patent: WO 98/54116 (1998-12-01), None
patent: WO 02/48131 (2002-06-01), None
patent: WO 2005/009954 (2005-02-01), None
patent: WO 2006/081389 (2006-08-01), None
patent: WO 2006/081391 (2006-08-01), None
patent: WO 2006/083477 (2006-08-01), None
patent: WO 2006/089177 (2006-08-01), None
patent: WO 2007/087429 (2007-08-01), None
patent: WO 2007/112093 (2007-10-01), None
patent: WO 2008/063504 (2008-05-01), None
Jordan, V. C. Nature Reviews: Drug Discovery, 2, 2003, 205.
Vippagunta, et al. Advanced Drug Delivery Reviews, 48, 2001, 18.
PubChem, http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=661910&loc, accessed Oct. 7, 2010.
PubChem Public Chemical Database, CID 1914390, created Jul. 13, 2005, http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=1914390&loc=ec—rcs, accessed Jan. 16, 2011.
PCT/US2008/073392 International Search Report dated Feb. 11, 2009.
ScienceIP search report dated Feb. 19, 2007.
ScienceIP search report dated Feb. 20, 2007.
Henry, “Calcium antagonists as antiatherogenic agents”, Ann N Y Acad Sci. 522:411-9, 1988.
Schepetkin et al., “High-throughput screening for small-molecule activators of neutrophils: identification of novel N-formyl peptide receptor agonists,” Mol Pharmacol. 71(4):1061-74, 2007.
Sweeney et al., “Small-molecule inhibitors of store-operated calcium entry,” ChemMedChem. 4(5):706-18, 2009.
Yonetoku et al., “Novel potent and selective Ca2+release-activated Ca2+(CRAC) channel inhibitors. Part 3: synthesis and CRAC channel inhibitory activity of 4′-[(trifluoromethyl)pyrazol-1-yl]carboxanilides,” Bioorg Med Chem. 16(21):9457-66, 2008.
Yonetoku et al., “Novel potent and selective calcium-release-activated calcium (CRAC) channel inhibitors. Part 1: synthesis and inhibitory activity of 5-(1-methy1-3-trifluoromethyl-1H-pyrazol-5-yl)-2-thiophenecarboxamides,” Bioorg Med Chem. 14(14):4750-60, 2006.
Yonetoku et al., “Novel potent and selective calcium-release-activated calcium (CRAC) channel inhibitors. Part 2: Synthesis and inhibitory activity of ary1-3-trifluoromethylpyrazoles,” Bioorg Med Chem. 14(15):5370-83, 2006.
Cao Jianguo
Dyck Brian
Grey Jonathan
Pei Yazhong
Rogers Evan
CalciMedica, Inc.
Willis Douglas M
Wilson James O.
Wilson Sonsini Goodrich & Rosati
LandOfFree
Compounds that modulate intracellular calcium does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds that modulate intracellular calcium, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds that modulate intracellular calcium will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2736896